Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma

This study has been terminated.
(Due to business considerations; not due to toxicities or adverse events.)
Oncolix, Inc.
Information provided by:
Greenville Hospital System University Medical Center Identifier:
First received: April 30, 2008
Last updated: April 7, 2009
Last verified: April 2009

The purpose of this study is to determine if treatment with the autologous cellular vaccine, Melaxin, in combination with Bacillus Calmette-Guerin (BCG) injections is effective in Stage IV malignant melanoma.

Condition Intervention Phase
Biological: Melaxin (autologous dendritoma vaccine) and BCG
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II, Open-Label Trial in Patients With Stage IV Malignant Melanoma Using Melaxin as a Cancer Vaccine in Conjunction With BCG

Resource links provided by NLM:

Further study details as provided by Greenville Hospital System University Medical Center:

Primary Outcome Measures:
  • Adverse events and clinical laboratory results [ Time Frame: From first vaccine to 6 weeks after the last ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Tumor response as measured using the RECIST criteria [ Time Frame: 18 months after last vaccine ] [ Designated as safety issue: No ]

Enrollment: 2
Study Start Date: April 2008
Study Completion Date: March 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: Melaxin (autologous dendritoma vaccine) and BCG
    Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.
    Other Name: Melaxin
Detailed Description:

Chemotherapy and immunotherapy are the main therapies for metastatic melanoma with the hope of prolonging survival. The ideal immunotherapy would consist of the professional antigen-presenting cell, the dendritic cell, with the entire repertoire of tumor antigens inside. The best way to achieve this is by creating an autologous hybrid fusion cell of the dendritic cell and tumor cell. In this study, melanoma tumor tissue surgically removed from the patient will be disassociated into single cells, irradiated and fused to dendritic cells produced by culturing the patient's blood monocytes. Prior to the electrofusion procedure, the tumor cells are stained red and the dendritic cells are stained green. After fusion, the uniquely colored fused cells, or dendritomas, are separated from the unfused cells by use of a fluorescence activated cell sorter. This highly purified population is then divided into 4 doses containing 250,000 dendritomas each and frozen. Each dose is thawed, diluted to 1 ml with Sterile Saline for Injection containing 5% human serum albumin and administered subcutaneously over a lymph node bed to the patient once every 4 weeks. A separate injection of BCG is administered in the same area within 10 minutes of the dendritoma injection. The safety and efficacy of the therapy will be evaluated in 25 patients.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability to give informed consent
  • Male or female patient whose age is > 18 years of age
  • Histological documented Stage IV malignant melanoma (AJCC sixth edition)
  • Pathology report from tumor specimen verifying melanoma diagnosis
  • Free of infection
  • Hemoglobin> 9.0gm/dL, WBC>3000/mm3, platelets> 100,000mm3
  • Liver function test that are less than 2 times the upper limit of normal of the reference range for the testing laboratory
  • Adequate cardiac function-any evidence of ischemic heart disease demonstrated by history, physical, or EKG will require referral to a cardiologist for evaluation and clearance prior to protocol therapy
  • No immunotherapy within the past 3 months
  • A minimum of 4 doses of lot-released, autologus Melaxin (1.0 million dendritomas)

Exclusion Criteria:

  • Other malignancies in the past 5 years with the exception of non-melanoma skin cancer or carcinoma in situ of the cervix
  • Has received any immunosuppressive agent within 30 days prior to treat
  • Creatinine> 2.5mg/dL or currently on dialysis
  • Positive serum pregnancy test, breast-feeding,or planning to conceive or father or father a child in the period surrounding the study as described in the informed consent.
  • Women of childbearing potential who cannot follow the directions for birth control
  • ECOG performance status greater than 3
  • Positive Rdonr panel (HIV 1, 2; HTLV 1,2; Hepatitis B and C)
  • History of a seizure disorder
  • Brain metastases that have progressed within the last 6 months
  • No measurable disease
  Contacts and Locations
Please refer to this study by its identifier: NCT00671554

United States, South Carolina
Cancer Center of Carolinas/Clinical Research Unit 3rd Floor
Greenville, South Carolina, United States, 29605
Sponsors and Collaborators
Greenville Hospital System University Medical Center
Oncolix, Inc.
Study Director: Thomas E Wagner, PhD Greenville Hospital System
  More Information

No publications provided

Responsible Party: Thomas E. Wagner, PhD/Director, Greenville Hospital System Identifier: NCT00671554     History of Changes
Other Study ID Numbers: CC/ORI 07-02
Study First Received: April 30, 2008
Last Updated: April 7, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Greenville Hospital System University Medical Center:
Dendritic cells
Cell therapy
BCG vaccine

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
BCG Vaccine
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions processed this record on April 17, 2014